B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells

In the treatment of metastatic melanoma, a highly therapy-refractory cancer, alkylating agents are used and, for the subgroup of BRAF(V600E) cancers, the B-Raf inhibitor vemurafenib. Although vemurafenib is initially beneficial, development of drug resistance occurs leading to tumor relapse, which n...

Descripción completa

Detalles Bibliográficos
Autores principales: Roos, Wynand P., Quiros, Steve, Krumm, Andrea, Merz, Stephanie, Switzeny, Olivier Jérôme, Christmann, Markus, Loquai, Carmen, Kaina, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350346/
https://www.ncbi.nlm.nih.gov/pubmed/25557167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350346/
https://www.ncbi.nlm.nih.gov/pubmed/25557167

Ejemplares similares